Precigen Reports Full Year 2025 Financial Results and Business Updates

March 26, 2026 - 05:08

Precigen, Inc. has officially transitioned into a commercial-stage biotechnology company, marking a transformative year in 2025. This shift follows the landmark US approval of PAPZIMEOS™ (zopapogene imadenovec-drba), the first-and-only treatment of its kind to receive FDA clearance for its specific indication. This achievement represents the culmination of years of research and development, positioning the company at the forefront of its therapeutic area.

Alongside this pivotal business update, Precigen announced its full-year financial results for 2025. The company reported a significant increase in revenue, directly attributed to the initial commercial launch of PAPZIMEOS™. This revenue growth underscores the market demand for this novel therapy. Management emphasized that these financial resources will be strategically reinvested to accelerate the commercial rollout, support ongoing clinical trials for other pipeline candidates, and fund further research initiatives.

Executives expressed confidence in the company's trajectory, highlighting that the approval and successful market introduction provide a solid foundation for sustainable growth. The focus is now on ensuring broad patient access to PAPZIMEOS™ while advancing a promising portfolio of genetic medicines designed to address serious diseases. The company's progress in 2025 sets a new course for its future operations and potential.